Total Payments
$175,166
2024 Payments
$9,473
Companies
53
Transactions
841
Medicare Patients
20,829
Medicare Billing
$610,721
Payment Breakdown by Category
Other$135,430 (77.3%)
Travel$20,127 (11.5%)
Food & Beverage$18,099 (10.3%)
Consulting$1,418 (0.8%)
Education$91.41 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,430 | 60 | 77.3% |
| Travel and Lodging | $20,127 | 68 | 11.5% |
| Food and Beverage | $18,099 | 695 | 10.3% |
| Consulting Fee | $1,418 | 4 | 0.8% |
| Education | $91.41 | 14 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $104,211 | 175 | $0 (2022) |
| Esperion Therapeutics, Inc. | $39,155 | 59 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,299 | 44 | $0 (2024) |
| Medicure Pharma Inc. | $5,611 | 8 | $0 (2023) |
| Boston Scientific Corporation | $2,728 | 34 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,197 | 68 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $909.93 | 66 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $806.79 | 41 | $0 (2024) |
| Amgen Inc. | $778.28 | 38 | $0 (2024) |
| PFIZER INC. | $696.31 | 44 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,473 | 100 | Esperion Therapeutics, Inc. ($7,725) |
| 2023 | $6,624 | 75 | Esperion Therapeutics, Inc. ($3,439) |
| 2022 | $10,547 | 91 | Esperion Therapeutics, Inc. ($9,200) |
| 2021 | $20,269 | 89 | Esperion Therapeutics, Inc. ($18,706) |
| 2020 | $16,668 | 65 | Amarin Pharma Inc. ($14,113) |
| 2019 | $50,409 | 160 | Amarin Pharma Inc. ($47,203) |
| 2018 | $24,923 | 129 | Amarin Pharma Inc. ($17,329) |
| 2017 | $36,253 | 132 | Amarin Pharma Inc. ($25,405) |
All Payment Transactions
841 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $13.49 | General |
| Category: Heart Failure and Hypertension | ||||||
| 12/21/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Cardiology | ||||||
| 11/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Not Applicable | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: DIABETES | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.69 | General |
| Category: Cardiovascular | ||||||
| 11/06/2024 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $6.98 | General |
| Category: WATCHMAN_IC | ||||||
| 11/05/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: WATCHMAN_IC | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/17/2024 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $145.74 | General |
| Category: WATCHMAN_IC | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: DIABETES | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.45 | General |
| Category: Cardiovascular | ||||||
| 09/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/25/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/23/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 5,645 | 7,418 | $430,347 | $158,200 |
| 2022 | 29 | 5,705 | 7,631 | $451,094 | $170,651 |
| 2021 | 28 | 5,355 | 7,108 | $401,256 | $156,524 |
| 2020 | 22 | 4,124 | 5,265 | $335,374 | $125,346 |
Total Patients
20,829
Total Services
27,422
Medicare Billing
$610,721
Procedure Codes
124
All Medicare Procedures & Services
124 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 599 | 617 | $82,761 | $32,656 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 311 | 460 | $66,700 | $28,176 | 42.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,772 | 3,896 | $70,128 | $24,569 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 145 | 220 | $46,860 | $20,197 | 43.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 70 | 153 | $22,338 | $9,507 | 42.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 409 | 410 | $18,860 | $6,752 | 35.8% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 60 | 60 | $10,920 | $3,804 | 34.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 276 | 277 | $8,587 | $3,009 | 35.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 199 | 305 | $14,335 | $2,900 | 20.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $8,526 | $2,877 | 33.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 39 | 47 | $8,507 | $2,877 | 33.8% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 47 | 116 | $8,004 | $2,339 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 40 | 51 | $7,395 | $2,237 | 30.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 37 | 70 | $5,711 | $2,094 | 36.7% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 47 | 115 | $7,360 | $1,749 | 23.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $4,400 | $1,645 | 37.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 15 | $3,840 | $1,363 | 35.5% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 62 | 62 | $3,348 | $1,067 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 17 | $3,621 | $1,052 | 29.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 53 | 53 | $2,862 | $1,039 | 36.3% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 109 | 110 | $8,800 | $971.56 | 11.0% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 19 | 19 | $2,869 | $965.48 | 33.7% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 54 | 59 | $3,186 | $799.91 | 25.1% |
| 93352 | Injection of x-ray contrast during ultrasound of heart | Facility | 2023 | 27 | 27 | $1,917 | $689.26 | 36.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 15 | $1,170 | $588.75 | 50.3% |
About Dr. Glenn Davison, M.D
Dr. Glenn Davison, M.D is a Cardiovascular Disease healthcare provider based in Chesterfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518924513.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Glenn Davison, M.D has received a total of $175,166 in payments from pharmaceutical and medical device companies, with $9,473 received in 2024. These payments were reported across 841 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($135,430).
As a Medicare-enrolled provider, Davison has provided services to 20,829 Medicare beneficiaries, totaling 27,422 services with total Medicare billing of $610,721. Data is available for 4 years (2020–2023), covering 124 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Chesterfield, MO
- Active Since 04/26/2006
- Last Updated 07/27/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1518924513
Products in Payments
- Vascepa (Drug) $104,211
- NEXLIZET (Drug) $33,078
- PRADAXA (Drug) $12,974
- NEXLETOL (Drug) $6,077
- WATCHMAN (Device) $2,161
- HMG-CoA reductase inhibitor (Drug) $1,800
- Zypitamag (Drug) $1,700
- ZYPITAMAG (pitavastatin) (Drug) $1,589
- XARELTO (Drug) $1,197
- ELIQUIS (Drug) $772.28
- ENTRESTO (Drug) $740.73
- BRILINTA (Drug) $604.49
- Repatha (Biological) $468.44
- LifeVest (Device) $425.08
- WATCHMAN Access System (Device) $388.91
- MULTAQ (Drug) $379.56
- VERQUVO (Drug) $361.53
- JARDIANCE (Drug) $320.20
- Corlanor (Drug) $309.84
- Barostim Neo System (Device) $246.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chesterfield
James Ellison, Md, MD
Cardiovascular Disease — Payments: $136,879
Cardiovascular Disease $136,879
Dr. Keith Mankowitz, Md, MD
Cardiovascular Disease — Payments: $73,624
Cardiovascular Disease $73,624
Dr. Jonas Cooper, Md, MD
Cardiovascular Disease — Payments: $45,608
Cardiovascular Disease $45,608
Dr. Craig Reiss, Md, MD
Cardiovascular Disease — Payments: $7,942
Cardiovascular Disease $7,942
Dr. Maged Haikal
Cardiovascular Disease — Payments: $4,137
Cardiovascular Disease $4,137
Salman Waheed, M.d., M.p.h, M.D., M.P.H
Cardiovascular Disease — Payments: $3,364
Cardiovascular Disease $3,364